Suven Life up over 3 pc on patent for neuro-degenerative drug

Shares of Suven Life Sciences rose by over 3 per cent today as the company has been granted one patent from Europe and two product patents from Eurasia for a drug used in the treatment of neuro-degenerative diseases.
The stock gained 2.98 per cent to Rs 210.30 on BSE.
At NSE, shares of the company went up 3.11 per cent to Rs 210.50.
In a BSE filing today, Suven Life said it has been granted "one product patent from Europe and two product patents from Eurasia corresponding to New Chemical Entities (NCEs) for treatment of disorders associated with neuro-degenerative diseases".

The patents are valid through 2029, 2030 and 2031, respectively, the company added.
With these clearances, Suven has a total of 21 granted patents from Europe and 19 from Eurasia.
Suven Life CEO Venkat Jasti said: "We are pleased by the grant of these patents to Suven for our pipeline of molecules in the CNS arena, which are being developed for cognitive disorders with high unmet medical need with a huge market potential globally.